Caricamento...
Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?
Anti-programmed cell death 1 (PD1) immunotherapies are among the most effective anti-cancer immunotherapies available; however, a large number of patients present with or develop resistance to them. Unfortunately, very little is known regarding the mechanisms of resistance to such therapies. A recen...
Salvato in:
| Pubblicato in: | Genome Med |
|---|---|
| Autori principali: | , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
BioMed Central
2016
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5080691/ https://ncbi.nlm.nih.gov/pubmed/27782862 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13073-016-0365-1 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|